The growing need for highly predictive models in preclinical phase of cancer drug development faces a critical hurdle: existing technologies can’t effectively fine-tune immune responses. Our innovative solution tackles this by creating a customizable, 3D in vitro platform.
This platform will revolutionize tumor modeling, drug delivery, and immune cell therapy testing. Expect significantly reduced animal testing, faster preclinical development, and far more accurate predictions than traditional methods.
Ultimately, our technology offers substantial cost savings, lowers drug failure rates, and provides a versatile tool to accelerate innovation in oncology and regenerative medicine, pushing therapeutic research forward.